Orlando, FL, December 7, 2019 – Legend Biotech announced today initial results from the Janssen Research &Development, LLC (Janssen)-sponsored Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed and/or […]

Orlando, FL, December 9, 2019 – Legend Biotech reported updated data on the LEGEND-2 (NCT03090659) Phase1/2 open-label, first-in-human study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy, LCAR-B38M, in the treatment of patients with advanced relapsed and/or refractory multiple myeloma (RRMM) in China. LCAR-B38M is a structurally differentiated CAR-T cell therapy containing a […]

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the […]

SOMERSET, N.J.—(BUSINESS WIRE)—May 31, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it will host an investor event during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Taking place on Sunday, June 5 at 6pm Central Time, […]

CARVYKTI® is Legend Biotech’s first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with relapsed or refractory multiple myeloma following a one-time treatment with ciltacabtagene autoleucel SOMERSET, N.J.— (BUSINESS WIRE)—May 26, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend […]